Eligobiotics is a new generation of antimicrobials that can be programmed to target bacteria based on their genome. Eligobiotics therefore provide a new approach to explore, understand and control bacterial ecosystems both in human and animals. They can notably be used to selectively eradicate harmful pathogens from the microbiome while sparing beneficial ones.
Paris-based Eligo Bioscience, a microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured $20 million in Series A financing. The investors included Khosla Ventures and Seventure Partners.